{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T05:29:31Z","timestamp":1787030971418,"version":"build-2736575974"},"reference-count":22,"publisher":"Scientific Scholar","issue":"2&3","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,2]]},"abstract":"\n Background & objectives:<\/jats:title>\n Vaccination will play an important role in meeting the end tuberculosis (TB) goals. While certain vaccine candidates in advanced stages of clinical trials raise hope for the future availability of new tools, in the immediate term, there is also increasing interest in Bacille Calmette\u2013Gu\u00e9rin revaccination among adults and adolescents as a potential strategy. Here, we sought to estimate the potential epidemiological impact of TB vaccination in India.<\/jats:p>\n <\/jats:sec>\n \n Methods:<\/jats:title>\n \n We developed a deterministic, age-structured, compartmental model of TB in India. Data from the recent national prevalence survey was used to inform epidemiological burden while also incorporating a vulnerable population who may be prioritized for vaccination, the latter consistent with the burden of undernutrition. Using this framework, the potential impact on incidence and mortality of a vaccine with 50 per cent efficacy was estimated, if rolled out in 2023 to cover 50 per cent of the unvaccinated each year. Simulated impacts were compared for disease-\n vs<\/jats:italic>\n . infection-preventing vaccines, as well as when prioritizing vulnerable groups (those with undernutrition) rather than the general population. A sensitivity analyses were also conducted with respect to the duration, and efficacy, of vaccine immunity.\n <\/jats:p>\n <\/jats:sec>\n \n Results:<\/jats:title>\n When rolled out in the general population, an infection-preventing vaccine would avert 12 per cent (95% Bayesian credible intervals (Crl): 4.3-28%) of cumulative TB incidence between 2023 and 2030, while a disease-preventing vaccine would avert 29 per cent (95% Crl: 24-34%). Although the vulnerable population accounts for only around 16 per cent of India\u2019s population, prioritizing this group for vaccination would achieve almost half the impact of rollout in the general population, in the example of an infection-preventing vaccine. Sensitivity analysis also highlights the importance of the duration and efficacy of vaccine-induced immunity.<\/jats:p>\n <\/jats:sec>\n \n Interpretation & conclusions:<\/jats:title>\n These results highlight how even a vaccine with moderate effectiveness (50%) could achieve substantial reductions in TB burden in India, especially when prioritized for the most vulnerable.<\/jats:p>\n <\/jats:sec>","DOI":"10.4103\/ijmr.ijmr_328_23","type":"journal-article","created":{"date-parts":[[2023,5,10]],"date-time":"2023-05-10T13:37:53Z","timestamp":1683725873000},"page":"119-126","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":4,"title":["The potential impact of vaccination on tuberculosis burden in India: A modelling analysis"],"prefix":"10.25259","volume":"157","author":[{"given":"Nimalan","family":"Arinaminpathy","sequence":"first","affiliation":[{"name":"MRC Centre for Global Infectious Disease Analysis, Imperial College London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kirankumar","family":"Rade","sequence":"additional","affiliation":[{"name":"WHO India Country Office, Ministry of Health & Family Welfare, New Delhi, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ravinder","family":"Kumar","sequence":"additional","affiliation":[{"name":"Central TB Division, Ministry of Health & Family Welfare, New Delhi, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajendra P.","family":"Joshi","sequence":"additional","affiliation":[{"name":"Central TB Division, Ministry of Health & Family Welfare, New Delhi, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raghuram","family":"Rao","sequence":"additional","affiliation":[{"name":"Central TB Division, Ministry of Health & Family Welfare, New Delhi, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10894","published-online":{"date-parts":[[2023,5,3]]},"reference":[{"key":"R3-20241212","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1186\/s12916-020-01651-5","article-title":"The potential impact of preventive therapy against tuberculosis in the WHO South-East Asian Region:A modelling approach","volume":"18","author":"Mandal","year":"2020","journal-title":"BMC Med"},{"key":"R4-20241212","first-page":"53","article-title":"Ethical issues in expanding latent TB management in high burden countries","author":"Basu","year":"2020;V","journal-title":"Indian J Med Ethics"},{"key":"R6-20241212","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1001\/jama.1994.03510330076038","article-title":"Efficacy of BCG vaccine in the prevention of tuberculosis. Meta-analysis of the published literature","volume":"271","author":"Colditz","year":"1994","journal-title":"JAMA"},{"key":"R7-20241212","doi-asserted-by":"crossref","first-page":"e1307","DOI":"10.1016\/S2214-109X(22)00283-2","article-title":"Infant BCG vaccination and risk of pulmonary and extrapulmonary tuberculosis throughout the life course:A systematic review and individual participant data meta-analysis","volume":"10","author":"Martinez","year":"2022","journal-title":"Lancet Glob Health"},{"key":"R9-20241212","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/S0140-6736(96)02166-6","article-title":"Randomised controlled trial of single BCG, repeated BCG, or combined BCG and killed Mycobacterium leprae vaccine for prevention of leprosy and tuberculosis in Malawi","volume":"348","year":"1996","journal-title":"Lancet"},{"key":"R10-20241212","doi-asserted-by":"crossref","first-page":"130540","DOI":"10.1172\/jci.insight.130540","article-title":"BCG revaccination boosts adaptive polyfunctional Th1\/Th17 and innate effectors in IGRA+and IGRA- Indian adults","volume":"4","author":"Rakshit","year":"2019","journal-title":"JCI Insight"},{"key":"R11-20241212","first-page":"819","article-title":"Trial of BCG vaccines in South India for tuberculosis prevention:First report \u2013Tuberculosis Prevention Trial","volume":"57","year":"1979","journal-title":"Bull World Health Organ"},{"key":"R12-20241212","doi-asserted-by":"crossref","first-page":"152","DOI":"10.4103\/ijmr.ijmr_1540_22","article-title":"Revisiting the Chingleput BCG vaccination trial for the impact of BCG revaccination on the incidence of tuberculosis disease","volume":"157","author":"Velayutham","year":"2022","journal-title":"Indian J Med Res"},{"key":"R13-20241212","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1056\/NEJMoa1714021","article-title":"Prevention of M. tuberculosis Infection with H4: IC31 vaccine or BCG revaccination","volume":"379","author":"Nemes","year":"2018","journal-title":"N Engl J Med"},{"key":"R14-20241212","doi-asserted-by":"crossref","first-page":"15520","DOI":"10.1073\/pnas.1404386111","article-title":"Impact and cost-effectiveness of new tuberculosis vaccines in low- and middle-income countries","volume":"111","author":"Knight","year":"2014","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R15-20241212","doi-asserted-by":"crossref","first-page":"13980","DOI":"10.1073\/pnas.0901720106","article-title":"Epidemiological benefits of more-effective tuberculosis vaccines, drugs, and diagnostics","volume":"106","author":"Abu-Raddad","year":"2009","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R16-20241212","doi-asserted-by":"crossref","first-page":"eaax4607","DOI":"10.1126\/scitranslmed.aax4607","article-title":"Potential impact of tuberculosis vaccines in China, South Africa, and India","volume":"12","author":"Harris","year":"2020","journal-title":"Sci Transl Med"},{"key":"R18-20241212","doi-asserted-by":"crossref","first-page":"e1002152","DOI":"10.1371\/journal.pmed.1002152","article-title":"The global burden of latent tuberculosis infection:A re-estimation using mathematical modelling","volume":"13","author":"Houben","year":"2016","journal-title":"PLoS Med"},{"key":"R19-20241212","doi-asserted-by":"crossref","first-page":"11","DOI":"10.4103\/0971-5916.193278","article-title":"Undernutrition &tuberculosis in India:Situation analysis &the way forward","volume":"144","author":"Padmapriyadarsini","year":"2016","journal-title":"Indian J Med Res"},{"key":"R20-20241212","doi-asserted-by":"crossref","first-page":"9","DOI":"10.4103\/0970-2113.45198","article-title":"Tuberculosis and nutrition","volume":"26","author":"Gupta","year":"2009","journal-title":"Lung India"},{"key":"R24-20241212","doi-asserted-by":"crossref","first-page":"e228","DOI":"10.1016\/S1473-3099(18)30134-8","article-title":"Progression from latent infection to active disease in dynamic tuberculosis transmission models:A systematic review of the validity of modelling assumptions","volume":"18","author":"Menzies","year":"2018","journal-title":"Lancet Infect Dis"},{"key":"R26-20241212","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1093\/clinids\/20.4.982","article-title":"Geographic latitude and the efficacy of Bacillus Calmette-Gu\u00e9rin vaccine","volume":"20","author":"Wilson","year":"1995","journal-title":"Clin Infect Dis"},{"key":"R27-20241212","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1016\/S1473-3099(20)30994-4","article-title":"The effect of BCG revaccination on all-cause mortality beyond infancy:30-year follow-up of a population-based, Double-Blind, randomised placebo-controlled trial in Malawi","volume":"21","author":"Glynn","year":"2021","journal-title":"Lancet Infect Dis"},{"key":"R28-20241212","doi-asserted-by":"crossref","first-page":"3810","DOI":"10.1038\/s41598-019-39799-7","article-title":"Modelling the impact of effective private provider engagement on tuberculosis control in Urban India","volume":"9","author":"Arinaminpathy","year":"2019","journal-title":"Sci Rep"},{"key":"R29-20241212","doi-asserted-by":"crossref","first-page":"2334","DOI":"10.1016\/S0140-6736(15)00322-0","article-title":"Turning off the tap:Stopping tuberculosis transmission through active case-finding and prompt effective treatment","volume":"386","author":"Yuen","year":"2015","journal-title":"Lancet"},{"key":"R30-20241212","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1186\/s12916-021-01932-7","article-title":"The epidemiologic impact and cost-effectiveness of new tuberculosis vaccines on multidrug-resistant tuberculosis in India and China","volume":"19","author":"Weerasuriya","year":"2021","journal-title":"BMC Med"},{"key":"R31-20241212","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1038\/s41467-020-20731-x","article-title":"Modelling the global burden of drug-resistant tuberculosis avertable by a post-exposure vaccine","volume":"12","author":"Fu","year":"2021","journal-title":"Nat Commun"}],"container-title":["Indian Journal of Medical Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.4103\/ijmr.ijmr_328_23","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T19:06:10Z","timestamp":1751483170000},"score":1,"resource":{"primary":{"URL":"https:\/\/ijmr.org.in\/the-potential-impact-of-vaccination-on-tuberculosis-burden-in-india-a-modelling-analysis\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2]]},"references-count":22,"journal-issue":{"issue":"2&3","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.4103\/ijmr.ijmr_328_23","relation":{},"ISSN":["0971-5916","0975-9174"],"issn-type":[{"value":"0971-5916","type":"print"},{"value":"0975-9174","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2]]},"assertion":[{"value":"2023-02-20","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}}]}}